Zentek Provides a Preliminary Update on Influenza Countermeasure Candidate Developed Using the Multivalent Aptamer Technology against H1N1 (Seasonal Influenza)

Core Viewpoint - Zentek Ltd. has successfully completed the first in vivo tests of its lead candidate countermeasure for seasonal influenza (H1N1) as part of the Innovative Solutions Canada Testing Stream [1] Company Summary - Zentek Ltd. is listed on Nasdaq under the ticker ZTEK and on TSX-V under the ticker ZEN [1]